On January 10th, Lilly Pharmaceuticals announced that Encore&Co; Reg; Jiakanezumab Injection has officially been approved by the National Medical Products Administration for the preventive treatment of adult migraines.
According to Eli Lilly Pharmaceuticals, Enjiale&Co; Reg; Jiakanezumab Injection is a humanized IgG4 type monoclonal antibody that can bind to calcitonin gene related peptide (CGRP) and block the binding of CGRP to its receptor, thereby achieving the therapeutic goal of preventing migraine. It is the first approved drug in China for the treatment of migraines by Eli Lilly Pharmaceuticals.
Jiakanezumab injection was approved for sale in the United States in September 2018 and has now been approved for sale in 60 countries and regions worldwide. (He Xinyi)